A new study from India has shed light on the effectiveness of buprenorphine maintenance treatment for women grappling with opioid dependence, offering a glimmer of hope amid a challenging landscape. Conducted at a tertiary addiction treatment centre in New Delhi, the research focused on a group of 43 Indian women who embarked on this long-term treatment between 2015 and 2023. The findings, published in the Indian Journal of Psychiatry, mark the first detailed exploration of how this approach fares among female patients in the country, a demographic often overlooked in addiction studies.
The women in the study, with a median age of 43, came from diverse backgrounds but shared common struggles. Most were married and living in nuclear families, often with limited formal education and lower socioeconomic status. Heroin emerged as the most commonly used opioid, followed by pharmaceutical drugs like pentazocine and tramadol, with nearly half of the participants having injected their substances at some point. Many turned to opioids initially for self-medication, particularly to alleviate pain, while others were drawn in by curiosity or family influences. Alongside their opioid dependence, a significant portion battled additional substance use, with tobacco topping the list, and faced psychiatric conditions such as mood disorders or physical health complications.
What sets this study apart is its revelation of buprenorphine’s tangible benefits. Over a median treatment duration of five years, an impressive 75% of the women remained engaged with the programme at the time of data collection. Self-reported abstinence reached 88%, and every urine drug screen conducted in the past year came back negative among those tested. Beyond these clinical wins, the treatment spurred remarkable improvements in everyday life. Social functioning saw a boost in over 97% of cases, family relationships strengthened for more than 92%, and occupational stability rose for nearly 92% of the participants. Early lapses into illicit opioid use, though recorded in about a quarter of the group, tended to fade as treatment progressed.
The success of this approach appears tied to several factors. Higher doses of buprenorphine, averaging 12 milligrams daily, combined with flexible dispensing schedules, such as weekly or fortnightly take-home supplies, likely played a role. Family involvement proved crucial too, with many women accompanied by relatives during treatment visits and nearly half receiving proxy dispensing through loved ones. This support network, coupled with the treatment’s outpatient feasibility, underscores its practicality in a country where women-specific addiction services remain scarce.
Despite its small sample size and retrospective design, the study challenges the notion that buprenorphine might falter for those dependent on pharmaceutical opioids, showing no notable difference in outcomes compared to illicit opioid users. For Indian women, who often face delayed treatment-seeking and complex comorbidities, these findings signal a viable path forward. As the nation grapples with rising substance use, this research not only highlights a working solution but also calls for broader, more inclusive studies to refine care for this vulnerable group.
